NCT04467840Phase 2, phase 3Completed

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

Study sponsor: RedHill Biopharma Limited

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2021-07-18Actual
Enrollment · participants475Actual
Source updated2025-07-31Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.